Safety-and-effectiveness Clinical Evaluation of Nanosecond-pulse Ablation for Atrial Fibrillation
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 166 participants.
Also called NCT06039722
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 166 participants
- Sponsor
- Shenzhen Pulsecare Medical Technology Co., Ltd.
- Registry
-
NCT06039722
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT06039722. Allocation not applicable; no masking; primary purpose treatment. Start 2022-11-03 (actual); primary completion 2024-08-29 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety-and-effectiveness Clinical Evaluation of Nanosecond-pulse Ablation for Atrial Fibrillation
- Acronym
- SCENA-AF
- Condition
- Paroxysmal Atrial Fibrillation
- Intervention (Device)
- Pulse ablation catheter
- Lead sponsor
- Shenzhen Pulsecare Medical Technology Co., Ltd.
Record details
- Record id
cardio:ct-nct06039722- Content hash
162b7da4605a77630c2b3dbb8b36665de247f833ddd525d226549cdc44f2b3ce